[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NZ760033A - Methods to treat opioid use disorder - Google Patents

Methods to treat opioid use disorder

Info

Publication number
NZ760033A
NZ760033A NZ760033A NZ76003318A NZ760033A NZ 760033 A NZ760033 A NZ 760033A NZ 760033 A NZ760033 A NZ 760033A NZ 76003318 A NZ76003318 A NZ 76003318A NZ 760033 A NZ760033 A NZ 760033A
Authority
NZ
New Zealand
Prior art keywords
use disorder
opioid use
methods
treat opioid
buprenorphine
Prior art date
Application number
NZ760033A
Inventor
Celine M Laffront
Malcolm A Young
Norma L Fox
Barbara R Haight
Susan M Learned
Original Assignee
Indivior Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indivior Uk Ltd filed Critical Indivior Uk Ltd
Publication of NZ760033A publication Critical patent/NZ760033A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Addiction (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The disclosure provides sustained-release buprenorphine formulations that produce therapeutic plasma concentration levels of buprenorphine in injection drug patients to treat opioid use disorder. The medicament is administered at a dosage level of 300 mg monthly for at least six months.
NZ760033A 2017-06-16 2018-06-15 Methods to treat opioid use disorder NZ760033A (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201762521121P 2017-06-16 2017-06-16
US201762572331P 2017-10-13 2017-10-13
US201762572996P 2017-10-16 2017-10-16
US201762598338P 2017-12-13 2017-12-13
US201862632995P 2018-02-20 2018-02-20
US201862656216P 2018-04-11 2018-04-11
US201862680935P 2018-06-05 2018-06-05
PCT/IB2018/000770 WO2018229551A2 (en) 2017-06-16 2018-06-15 Methods to treat opioid use disorder

Publications (1)

Publication Number Publication Date
NZ760033A true NZ760033A (en) 2023-02-24

Family

ID=63407480

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ760033A NZ760033A (en) 2017-06-16 2018-06-15 Methods to treat opioid use disorder

Country Status (5)

Country Link
EP (1) EP3638240A2 (en)
AU (1) AU2018283724B2 (en)
IL (1) IL271430A (en)
NZ (1) NZ760033A (en)
WO (1) WO2018229551A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016071767A1 (en) 2014-11-07 2016-05-12 Indivior Uk Limited Buprenorphine dosing regimens

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005249274B2 (en) 2004-06-04 2011-02-24 Camurus Ab Liquid depot formulations
EP1843751B1 (en) 2005-01-21 2020-09-30 Camurus Ab Pharmaceutical lipid compositions
US8975270B2 (en) 2010-06-08 2015-03-10 Rb Pharmaceuticals Limited Injectable flowable composition comprising buprenorphine
GB2481018B (en) 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
WO2016071767A1 (en) * 2014-11-07 2016-05-12 Indivior Uk Limited Buprenorphine dosing regimens
AU2016349111A1 (en) 2015-11-04 2018-05-17 Indivior Uk Limited Quantification of drugs in biological samples

Also Published As

Publication number Publication date
IL271430A (en) 2020-01-30
WO2018229551A2 (en) 2018-12-20
EP3638240A2 (en) 2020-04-22
WO2018229551A3 (en) 2019-02-14
AU2018283724A1 (en) 2020-01-16
AU2018283724B2 (en) 2021-08-19
AU2018283724A2 (en) 2020-01-23

Similar Documents

Publication Publication Date Title
MX2022005994A (en) Use of fak inhibitor in preparation of drug for treating tumors having nras mutation.
MX2021008247A (en) Combination of dextromethorphan and bupropion for treating depression.
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington's disease
MX2022003072A (en) Use of pridopidine for treating functional decline.
PE20142319A1 (en) MULTIPLE SCLEROSIS TREATMENT WITH A COMBINATION OF LAQUINIMOD AND GLATIRAMER ACETATE
MX2019003173A (en) Combination therapy with controlled-release cnp agonists.
RU2017134443A (en) METHOD OF TREATMENT WITH USE OF TRADIPTANT
MX2017006938A (en) Combination therapy for treatment of cancer.
MX2022015629A (en) Use of vibegron to treat overactive bladder.
MX2018013715A (en) Aqueous based capsaicinoid formulations, and treatment in combination with a corticosteroid.
MX2016006179A (en) Aqueous based capsaicinoid formulations and methods of manufacture and use.
EA202090242A1 (en) TREATMENT OF FABRY DISEASE IN FZT-NAIVE AND FZT-TREATED PATIENTS
BR112019002461A2 (en) Dosage regimen for solid tumor treatment
MX2015009546A (en) Increased dosage of efavirenz for the treatment of cancer.
JP2016505050A5 (en)
NZ751972A (en) Treatment of prurigo nodularis
MX2015016418A (en) Dihydroetorphine for the provision of pain relief and anaesthesia.
NZ760033A (en) Methods to treat opioid use disorder
MY193963A (en) Composition for treating joint diseases and kit containing same
MX2018005298A (en) Dosage regimen for a phosphatidylinositol 3-kinase inhibitor.
JOP20170044B1 (en) Pharmaceutical composition comprising recombinant hgh for the treatment of growth hormone deficiency
MX2018005876A (en) Plasminogen dosage regimen for wound healing.
EA202090416A1 (en) METHODS FOR TREATING GASTROPARESIS SYMPTOMS USING A VELUSETRAGA
EA201590323A1 (en) METHOD OF INTRODUCTION OF ACTIVE SUBSTANCES IN THE HEAD BRAIN
ZA202205914B (en) Methods for treating behavioral and psychological symptoms in patients with dementia

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 JUN 2025 BY COMPUTER PACKAGES INC

Effective date: 20240517